

Joseph H Antin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9396562/publications.pdf>

Version: 2024-02-01

198
papers

13,016
citations

34105
52
h-index

24982
109
g-index

315
all docs

315
docs citations

315
times ranked

11825
citing authors

#	ARTICLE	IF	CITATIONS
1	Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation. <i>Journal of Clinical Oncology</i> , 2022, 40, 189-201.	1.6	79
2	GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized, double-blinded, phase 2 trial. <i>Blood Advances</i> , 2022, 6, 2183-2194.	5.2	12
3	Umbilical Cord Blood or HLA-Haploidentical Transplantation: Real-World Outcomes versus Randomized Trial Outcomes. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 109.e1-109.e8.	1.2	12
4	Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapse. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	48
5	Invasive Yeast Infection after Haploidentical Donor Hematopoietic Cell Transplantation Associated with Cytokine Release Syndrome. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 508.e1-508.e8.	1.2	6
6	Characteristics of Graft-Versus-Host Disease (GvHD) After Post-Transplantation Cyclophosphamide Versus Conventional GvHD Prophylaxis. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 681-693.	1.2	13
7	Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant?. <i>Leukemia</i> , 2021, 35, 1166-1175.	7.2	5
8	Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial. <i>Blood</i> , 2021, 137, 420-428.	1.4	119
9	Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host disease. <i>Bone Marrow Transplantation</i> , 2021, 56, 1006-1012.	2.4	15
10	Impaired T- and NK-cell reconstitution after haploidentical HCT with posttransplant cyclophosphamide. <i>Blood Advances</i> , 2021, 5, 352-364.	5.2	58
11	COVID-19 and hematopoietic stem cell transplantation and immune effector cell therapy: a US cancer center experience. <i>Blood Advances</i> , 2021, 5, 861-871.	5.2	23
12	Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation. <i>Blood</i> , 2021, 137, 3212-3217.	1.4	24
13	HLA Haploidentical versus Matched Unrelated Donor Transplants with Post-Transplant Cyclophosphamide based prophylaxis. <i>Blood</i> , 2021, 138, 273-282.	1.4	88
14	SLC25A38 congenital sideroblastic anemia: Phenotypes and genotypes of 31 individuals from 24 families, including 11 novel mutations, and a review of the literature. <i>Human Mutation</i> , 2021, 42, 1367-1383.	2.5	11
15	Allogeneic hematopoietic cell transplantation outcomes in patients with Richter's transformation. <i>Haematologica</i> , 2021, 106, 3219-3222.	3.5	15
16	Ibrutinib in Steroid-Refractory Chronic Graft-versus-Host Disease, a Single-Center Experience. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 990.e1-990.e7.	1.2	16
17	Phase II Clinical Trial of Abatacept for Steroid-Refractory Chronic Graft Versus Host Disease. <i>Blood</i> , 2021, 138, 264-264.	1.4	3
18	Incidence, Predictors, and Outcomes of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 529-539.	2.0	14

#	ARTICLE	IF	CITATIONS
19	The role of regulatory T cells in graft-versus-host disease management. Expert Review of Hematology, 2020, 13, 141-154.	2.2	33
20	Tandem Autologous-Autologous versus Autologous-Allogeneic Hematopoietic Stem Cell Transplant for Patients with Multiple Myeloma: Long-Term Follow-Up Results from the Blood and Marrow Transplant Clinical Trials Network 0102 Trial. Biology of Blood and Marrow Transplantation, 2020, 26, 798-804.	2.0	28
21	Hematopoietic Stem Cell Transplantation for Shwachman-Diamond Syndrome. Biology of Blood and Marrow Transplantation, 2020, 26, 1446-1451.	2.0	24
22	Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia. Blood Advances, 2020, 4, 4113-4123.	5.2	22
23	Short telomere length predicts nonrelapse mortality after stem cell transplantation for myelodysplastic syndrome. Blood, 2020, 136, 3070-3081.	1.4	25
24	Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT. Journal of Clinical Oncology, 2020, 38, 2062-2076.	1.6	36
25	BK virus-specific T-cell immune reconstitution after allogeneic hematopoietic cell transplantation. Blood Advances, 2020, 4, 1881-1893.	5.2	16
26	Priorities for Improving Outcomes for Nonmalignant Blood Diseases: A Report from the Blood and Marrow Transplant Clinical Trials Network. Biology of Blood and Marrow Transplantation, 2020, 26, e94-e100.	2.0	3
27	Regression of oral proliferative leukoplakia following initiation of ibrutinib therapy in two allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplantation, 2020, 55, 1844-1846.	2.4	2
28	Therapeutic options for steroid-refractory acute and chronic GVHD: an evolving landscape. Expert Review of Hematology, 2020, 13, 519-532.	2.2	20
29	Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial. Blood, 2020, 135, 97-107.	1.4	56
30	Inhibition of inositol kinase B controls acute and chronic graft-versus-host disease. Blood, 2020, 135, 28-40.	1.4	14
31	Defibrotide: Real World Experience for Management of Veno-Occlusive Disease/ Sinusoidal Obstructive Syndrome after Hematopoietic Stem Cell Transplantation. Blood, 2020, 136, 23-24.	1.4	0
32	Cytokine-Induced Memory-like NK Cells Exhibit Massive Expansion and Long-Term Persistence after Infusion Post-Haploidentical Stem Cell Transplantation: A Report of the First Three Cases in a Phase I Trial. Blood, 2020, 136, 8-9.	1.4	4
33	Comparison of Outcomes after Haploidentical Relative and HLA Matched Unrelated Donor Transplantation with Post-Transplant Cyclophosphamide Containing Gvhd Prophylaxis Regimens. Blood, 2020, 136, 21-22.	1.4	0
34	Early Reconstitution of CD6+ T Cells after Hematopoietic Cell Transplantation Identifies a Suitable Target for Acute Graft Versus Host Disease Treatment Using Anti-CD6 Monoclonal Antibody Itolizumab. Blood, 2020, 136, 10-11.	1.4	1
35	Outcomes of IDH1- and IDH2-Mutated AML Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. Blood, 2020, 136, 2-3.	1.4	0
36	Impact of IL-6R Blockade for Cytokine Release Syndrome in Haploidentical Donor Stem Cell Transplant Patients on Infections, Clinical Outcomes and Immune Reconstitution. Blood, 2020, 136, 12-13.	1.4	0

#	ARTICLE	IF	CITATIONS
37	Safety and Efficacy of Adding Venetoclax to Reduced Intensity Conditioning Chemotherapy Prior to Allogeneic Hematopoietic Cell Transplantation in Patients with High Risk Myeloid Malignancies. Blood, 2020, 136, 38-39.	1.4	12
38	Early Clinical Predictors of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Myeloablative Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 137-144.	2.0	36
39	Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 73-85.	2.0	35
40	Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report. Clinical Cancer Research, 2019, 25, 5143-5155.	7.0	10
41	Reactivation of BK virus after double umbilical cord blood transplantation in adults correlates with impaired reconstitution of CD4+ and CD8+ T effector memory cells and increase of T regulatory cells. Clinical Immunology, 2019, 207, 18-23.	3.2	10
42	Whole blood RNA sequencing reveals a unique transcriptomic profile in patients with ARDS following hematopoietic stem cell transplantation. Respiratory Research, 2019, 20, 15.	3.6	16
43	Inferior Outcomes with Cyclosporine and Mycophenolate Mofetil after Myeloablative Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 1744-1755.	2.0	10
44	Positive psychological experiences in allogeneic hematopoietic stem cell transplantation. Psycho-Oncology, 2019, 28, 1633-1639.	2.3	15
45	Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203). Lancet Haematology, 2019, 6, e132-e143.	4.6	200
46	Targeting PI3K γ function for amelioration of murine chronic graft-versus-host disease. American Journal of Transplantation, 2019, 19, 1820-1830.	4.7	9
47	Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children. Blood Advances, 2019, 3, 2550-2561.	5.2	44
48	Recurrent genetic HLA loss in AML relapsed after matched unrelated allogeneic hematopoietic cell transplantation. Blood Advances, 2019, 3, 2199-2204.	5.2	52
49	Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia. Blood Advances, 2019, 3, 3123-3131.	5.2	37
50	Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease. Blood, 2019, 133, 94-99.	1.4	21
51	$\hat{1}\pm 1$ -Antitrypsin infusion for treatment of steroid-resistant acute graft-versus-host disease. Blood, 2018, 131, 1372-1379.	1.4	81
52	Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. Nature Medicine, 2018, 24, 282-291.	30.7	216
53	Phase 1 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease. Blood, 2018, 131, 2836-2845.	1.4	30
54	Safety and immunogenicity of conjugate quadrivalent meningococcal vaccination after hematopoietic cell transplantation. Blood Advances, 2018, 2, 1272-1276.	5.2	9

#	ARTICLE	IF	CITATIONS
55	Final results from a defibrotide treatmentâ€‹INDâ€‹ study for patients with hepatic venoâ€‹occlusive disease/sinusoidal obstruction syndrome. British Journal of Haematology, 2018, 181, 816-827.	2.5	95
56	Cytomegalovirus Infection Among Cord Blood Allogeneic Transplantation Recipients: Low Incidence of Cytomegalovirus Events without High-Dose Valacyclovir Prophylaxis. Biology of Blood and Marrow Transplantation, 2018, 24, 2164-2165.	2.0	3
57	Defibrotide for the treatment of hepatic venoâ€‹occlusive disease/sinusoidal obstruction syndrome following nontransplantâ€‹associated chemotherapy: Final results from a post hoc analysis of data from an expandedâ€‹access program. Pediatric Blood and Cancer, 2018, 65, e27269.	1.5	25
58	Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma. Journal of Clinical Oncology, 2017, 35, 1598-1605.	1.6	339
59	Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma. Blood, 2017, 129, 1380-1388.	1.4	209
60	PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy. Blood, 2017, 129, 2186-2197.	1.4	156
61	Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation. New England Journal of Medicine, 2017, 376, 536-547.	27.0	586
62	Donor-engrafted CHIP is common among stem cell transplant recipients with unexplained cytopenias. Blood, 2017, 130, 91-94.	1.4	78
63	Earlier defibrotide initiation postâ€‹diagnosis of venoâ€‹occlusive disease/sinusoidal obstruction syndrome improves Day +100 survival following haematopoietic stem cell transplantation. British Journal of Haematology, 2017, 178, 112-118.	2.5	72
64	Venous thromboembolism is associated with graft-â€‹versusâ€‹-host disease and increased non-relapse mortality after allogeneic hematopoietic stem cell transplantation. Haematologica, 2017, 102, 1185-1191.	3.5	31
65	Defibrotide for Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome: Interim Results from a Treatment IND Study. Biology of Blood and Marrow Transplantation, 2017, 23, 997-1004.	2.0	47
66	Improved survival after acute graft-â€‹versusâ€‹-host disease diagnosis in the modern era. Haematologica, 2017, 102, 958-966.	3.5	79
67	Plasma biomarkers of risk for death in a multicenter phase 3 trial with uniform transplant characteristics postâ€‹â€‹allogeneic HCT. Blood, 2017, 129, 162-170.	1.4	75
68	Lack of impact of umbilical cord blood unit processing techniques on clinical outcomes in adult double cord blood transplant recipients. Cytotherapy, 2017, 19, 272-284.	0.7	13
69	Readmissions after Umbilical Cord Blood Transplantation and Impact on Overall Survival. Biology of Blood and Marrow Transplantation, 2017, 23, 113-118.	2.0	6
70	ATG in allogeneic stem cell transplantation: standard of care in 2017? Counterpoint. Blood Advances, 2017, 1, 573-576.	5.2	27
71	Vaccination with autologous myeloblasts admixed with GM-K562 cells in patients with advanced MDS or AML after allogeneic HSCT. Blood Advances, 2017, 1, 2269-2279.	5.2	16
72	Relationship Between Intestinal Bacteria and the Anticancer Effect of Hematopoietic Stem-Cell Transplantation. Journal of Clinical Oncology, 2017, 35, 1636-1637.	1.6	1

#	ARTICLE	IF	CITATIONS
73	An activated Th17-prone T cell subset involved in chronic graft-versus-host disease sensitive to pharmacological inhibition. JCI Insight, 2017, 2, .	5.0	53
74	A Retrospective Chart Review to Assess Burden of Illness Among Patients with Severe Aplastic Anemia with Insufficient Response to Immunosuppressive Therapy. Blood, 2017, 130, 678-678.	1.4	2
75	Low-dose IL-2 selectively activates subsets of CD4+ Tregs and NK cells. JCI Insight, 2016, 1, e89278.	5.0	126
76	The addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial. British Journal of Haematology, 2016, 173, 96-104.	2.5	53
77	Allogeneic transplantation is not superior to chemotherapy in most patients over 40 years of age with Philadelphia-negative acute lymphoblastic leukemia in first remission. American Journal of Hematology, 2016, 91, 793-799.	4.1	14
78	Infused total nucleated cell dose is a better predictor of transplant outcomes than CD34 ⁺ cell number in reduced-intensity mobilized peripheral blood allogeneic hematopoietic cell transplantation. Haematologica, 2016, 101, 499-505.	3.5	43
79	Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism. Blood, 2016, 127, 2144-2154.	1.4	145
80	The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy. Blood, 2016, 127, 260-267.	1.4	245
81	Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD. Blood, 2016, 127, 646-657.	1.4	145
82	Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. Blood, 2016, 127, 1656-1665.	1.4	255
83	Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. Blood, 2016, 127, 2427-2438.	1.4	403
84	Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease. Blood, 2016, 128, 130-137.	1.4	176
85	An Open-Label Phase II Randomized Trial of Topical Dexamethasone and Tacrolimus Solutions for the Treatment of Oral Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2016, 22, 2084-2091.	2.0	16
86	Infection Rates among Acute Leukemia Patients Receiving Alternative Donor Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 1636-1645.	2.0	71
87	A phase I study of CD25/regulatory T-cell-depleted donor lymphocyte infusion for relapse after allogeneic stem cell transplantation. Haematologica, 2016, 101, 1251-1259.	3.5	27
88	Fludarabine/Busulfan versus Fludarabine/Melphalan Conditioning in Patients Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Lymphoma. Biology of Blood and Marrow Transplantation, 2016, 22, 1808-1815.	2.0	29
89	Circulating T follicular helper cells with increased function during chronic graft-versus-host disease. Blood, 2016, 127, 2489-2497.	1.4	92
90	Emerging drugs for graft-versus-host disease. Expert Opinion on Emerging Drugs, 2016, 21, 209-218.	2.4	7

#	ARTICLE	IF	CITATIONS
91	Improved Treatment-Related Mortality and Overall Survival of Patients with Grade IV Acute GVHD in the Modern Years. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 910-918.	2.0	32
92	Phase I Clinical Trial Evaluating Abatacept in Patient with Steroid-Refractory Chronic Graft Versus Host Disease. <i>Blood</i> , 2016, 128, 387-387.	1.4	2
93	Timing of Initiation of Defibrotide Post-Diagnosis of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome Post-Hematopoietic Stem Cell Transplantation: Exploratory Age-Group Analysis from an Expanded Access Study. <i>Blood</i> , 2016, 128, 66-66.	1.4	3
94	Genetic Alterations Predict Outcomes in Patients with Myelodysplastic Syndrome Receiving Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2016, 128, 69-69.	1.4	2
95	Double-Hit and Double-Expressor Lymphomas Are Not Associated with an Adverse Outcome after Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2016, 128, 830-830.	1.4	3
96	Clonal Hematopoiesis Associated with Adverse Outcomes Following Autologous Stem Cell Transplantation for Non-Hodgkin Lymphoma. <i>Blood</i> , 2016, 128, 986-986.	1.4	3
97	Follistatin and Endoglin: Potential Biomarkers of Endothelial Damage and Non-Relapse Mortality after Myeloablative Allogeneic Hematopoietic Cell Transplantation in Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0402. <i>Blood</i> , 2016, 128, 63-63.	1.4	0
98	Bortezomib-Based Versus Standard of Care Reduced Intensity Conditioning Hematopoietic Stem Cell Transplantation: A Phase II Randomized Controlled Trial. <i>Blood</i> , 2016, 128, 508-508.	1.4	3
99	BK Virus-Specific T Cell Immune Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2016, 128, 3425-3425.	1.4	0
100	Donor Chip Causes Donor-Derived Clonal Hematopoiesis As an Early Complication of Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2016, 128, 987-987.	1.4	0
101	Functional Effects of Low-Dose IL-2 in Patients with Chronic Graft Versus Host Disease. <i>Blood</i> , 2016, 128, 667-667.	1.4	4
102	Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease. <i>Blood</i> , 2015, 125, 4085-4094.	1.4	101
103	Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. <i>Blood</i> , 2015, 126, 1033-1040.	1.4	565
104	The Utility of Routine Chest Radiography in the Initial Evaluation of Adult Patients With Febrile Neutropenia Patients Undergoing HSCT. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 184-189.	4.9	11
105	Efficacy of immune suppression tapering in treating relapse after reduced intensity allogeneic stem cell transplantation. <i>Haematologica</i> , 2015, 100, 1222-1227.	3.5	24
106	Tacrolimus versus Cyclosporine after Hematopoietic Cell Transplantation for Acquired Aplastic Anemia. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1776-1782.	2.0	13
107	Risk Factors for Readmission after Allogeneic Hematopoietic Stem Cell Transplantation and Impact on Overall Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 509-516.	2.0	32
108	Absolute Lymphocyte Count Recovery after Allogeneic Hematopoietic Stem Cell Transplantation Predicts Clinical Outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 873-880.	2.0	56

#	ARTICLE	IF	CITATIONS
109	A Refined Risk Score for Acute Graft-versus-Host Disease that Predicts Response to Initial Therapy, Survival, and Transplant-Related Mortality. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 761-767.	2.0	195
110	Center for International Blood and Marrow Transplant Research Chronic Graft-versus-Host Disease Risk Score Predicts Mortality in an Independent Validation Cohort. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 640-645.	2.0	23
111	Long-Term Survival after Transplantation of Unrelated Donor Peripheral Blood or Bone Marrow Hematopoietic Cells for Hematologic Malignancy. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 55-59.	2.0	34
112	Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant (HSCT) after Treatment with Programmed Cell Death 1 (PD-1) Inhibitors. <i>Blood</i> , 2015, 126, 2018-2018.	1.4	5
113	Antigen Level Matching at HLA-C Improves Long-Term Outcomes after Double Umbilical Cord Blood Transplantation. <i>Blood</i> , 2015, 126, 2022-2022.	1.4	1
114	Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome with Multi-Organ Dysfunction: Final Results from a Pivotal, Historically Controlled, Phase 3 Trial. <i>Blood</i> , 2015, 126, 737-737.	1.4	1
115	A Multicenter Phase I/Ib Study of Ipilimumab for Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2015, 126, 860-860.	1.4	5
116	IL-7 and SCF Levels Inversely Correlate with T Cell Reconstitution and Clinical Outcomes after Cord Blood Transplantation in Adults. <i>PLoS ONE</i> , 2015, 10, e0132564.	2.5	22
117	Patients over Age 40 with Ph-Negative Acute Lymphoblastic Leukemia Do Not Benefit from Allogeneic Transplant in First Remission. Retrospective Analysis from a Large Tertiary Center. <i>Blood</i> , 2015, 126, 1304-1304.	1.4	0
118	The Use of Busulphan As Compared to Melphalan in Combination with Fludarabine in the Reduced Intensity Conditioning Improves Overall Survival in Patients with Lymphoma. <i>Blood</i> , 2015, 126, 2007-2007.	1.4	0
119	Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. <i>Journal of Clinical Investigation</i> , 2014, 124, 4867-4876.	8.2	173
120	Increased mitochondrial apoptotic priming of human regulatory T cells after allogeneic hematopoietic stem cell transplantation. <i>Haematologica</i> , 2014, 99, 1499-1508.	3.5	15
121	Somatic Mutations Predict Poor Outcome in Patients With Myelodysplastic Syndrome After Hematopoietic Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2014, 32, 2691-2698.	1.6	359
122	Effect of Antithymocyte Globulin Source on Outcomes of Bone Marrow Transplantation for Severe Aplastic Anemia. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, S27.	2.0	2
123	Live Attenuated Varicella-Zoster Vaccine in Hematopoietic Stem Cell Transplantation Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 285-287.	2.0	51
124	Iron Overload in Allogeneic Hematopoietic Cell Transplantation Outcome: A Meta-Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1248-1251.	2.0	64
125	Characterization of Oral Involvement in Acute Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1717-1721.	2.0	33
126	BK Virus Disease after Allogeneic Stem Cell Transplantation: A Cohort Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 564-570.	2.0	61

#	ARTICLE	IF	CITATIONS
127	Post-Transplantation B Cell Activating Factor and B Cell Recovery before Onset of Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 668-675.	2.0	45
128	Allotransplantation for Patients Age ≥40 Years with Non-Hodgkin Lymphoma: Encouraging Progression-Free Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 960-968.	2.0	37
129	Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans. <i>Blood</i> , 2014, 123, 3988-3998.	1.4	179
130	Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. <i>Blood</i> , 2014, 123, 3664-3671.	1.4	730
131	Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT. <i>Blood</i> , 2014, 124, 1372-1377.	1.4	178
132	Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802. <i>Blood</i> , 2014, 124, 3221-3227.	1.4	92
133	Homeostatic Reconstitution of CD4+ Regulatory and Conventional T Cell Subsets in Adult Patients after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT). <i>Blood</i> , 2014, 124, 2496-2496.	1.4	1
134	Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Dyskeratosis Congenita. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1238-1243.	2.0	108
135	Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans. <i>Blood</i> , 2012, 119, 1570-1580.	1.4	221
136	Autologous Whole Tumor Cell Vaccination Early After Allogeneic Stem Cell Transplantation Elicits Anti-Tumor T Cell Responses in Patients with Advanced Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2012, 120, 1892-1892.	1.4	0
137	Impact of White Blood Cell Count Recovery On Clinical Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2012, 120, 4136-4136.	1.4	0
138	Outcome and Prognostic Factors for Patients Who Relapse After Allogeneic Stem Cell Transplantation.. <i>Blood</i> , 2012, 120, 3069-3069.	1.4	5
139	SNP-Based Bayesian Networks Define Oral Mucositis Risk in Patients Receiving Stomatotoxic Conditioning Regimens for Autologous Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2012, 120, 735-735.	1.4	0
140	Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease. <i>New England Journal of Medicine</i> , 2011, 365, 2055-2066.	27.0	996
141	Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease. <i>Blood</i> , 2011, 117, 2275-2283.	1.4	115
142	Response to Helsby and Tingle. <i>American Journal of Hematology</i> , 2011, 86, 384-384.	4.1	1
143	Fludarabine-Based Conditioning for Allogeneic Marrow Transplantation From Unrelated Donors in Severe Aplastic Anemia (SAA): Serious and Unexpected Adverse Events in Pre-Defined Cyclophosphamide (CY) Dose Levels. <i>Blood</i> , 2011, 118, 3009-3009.	1.4	0
144	Molecular Ontogeny of Donor-Derived Lymphomas Occurring After Transplantation,. <i>Blood</i> , 2011, 118, 3671-3671.	1.4	0

#	ARTICLE	IF	CITATIONS
145	Does Iron Overload Really Matter in Stem Cell Transplantation?. Blood, 2011, 118, 3029-3029.	1.4	0
146	A Disease and Stage Risk Grouping System for Patients Undergoing Allogeneic Stem Cell Transplantation. Blood, 2011, 118, 327-327.	1.4	0
147	Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation. Journal of Clinical Investigation, 2010, 120, 1479-1493.	8.2	212
148	Reply to J. Mehta. Journal of Clinical Oncology, 2009, 27, e139-e140.	1.6	0
149	Up-Regulation of $\alpha 4 \beta 7$ Integrin on Peripheral T Cell Subsets Correlates with the Development of Acute Intestinal Graft-versus-Host Disease following Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2009, 15, 1066-1076.	2.0	45
150	Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. Blood, 2009, 113, 3865-3874.	1.4	285
151	Immune Reconstitution and Clinical Outcome After Donor Lymphocyte Infusion for Relapsed Disease After Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation in Diseases Other Than Chronic Myelogenous Leukemia.. Blood, 2009, 114, 3316-3316.	1.4	2
152	Factor VIII Is a Potential Autosomal B Cell Minor Histocompatibility Antigen in Chronic Gvhd.. Blood, 2009, 114, 1167-1167.	1.4	0
153	Chronic GVHD Is Associated with a BAFF Driven BCR-Activated B Cell Repertoire.. Blood, 2007, 110, 166-166.	1.4	1
154	Double Umbilical Cord Blood Transplantation with Reduced Intensity Conditioning and Sirolimus-Based GVHD Prophylaxis.. Blood, 2007, 110, 2016-2016.	1.4	1
155	Tacrolimus and Sirolimus without Methotrexate as Acute GVHD Prophylaxis after Matched Related Donor Reduced Intensity Conditioning (RIC) Stem Cell Transplantation (SCT).. Blood, 2007, 110, 3046-3046.	1.4	1
156	Non-Myeloablative Allogeneic Transplantation for Hodgkin's and Non-Hodgkin's Lymphoma: Evidence for a Graft-Versus-Lymphoma Effect and Relevance of Chimerism.. Blood, 2007, 110, 3041-3041.	1.4	0
157	Impact of Cytogenetics and Prior Therapy on Outcome of AML and MDS after Allogeneic Transplantation.. Blood, 2006, 108, 259-259.	1.4	1
158	Risk of HHV6-Associated Post-Transplant Acute Limbic Encephalitis (PALE) after Umbilical Cord Blood Stem Cell Transplantation: A Cohort Analysis.. Blood, 2006, 108, 2929-2929.	1.4	1
159	Effects of Cord Blood Cell Subset Populations in the Development of the Dominant Cord Blood Unit in Non-Myeloablative Sequential Double Cord Blood Transplantation (DCBT).. Blood, 2006, 108, 3148-3148.	1.4	1
160	GM-CSF Secreting Leukemia Cell Vaccinations after Allogeneic Reduced-Intensity Peripheral Blood Stem Cell Transplantation (SCT) for Advanced Myelodysplastic Syndrome (MDS) or Refractory Acute Myeloid Leukemia (AML).. Blood, 2006, 108, 3680-3680.	1.4	1
161	Prognostic Impact of Elevated Serum Ferritin in Patients Undergoing Myeloablative Stem Cell Transplantation.. Blood, 2006, 108, 595-595.	1.4	2
162	Costs of Complications after Allogeneic Myeloablative Stem Cell Transplantation.. Blood, 2006, 108, 2977-2977.	1.4	0

#	ARTICLE	IF	CITATIONS
163	Long-Term Outcome of Methotrexate-Free GVHD Prophylaxis Using Sirolimus and Tacrolimus in Matched Related (MRD) and Unrelated Donor (URD) Peripheral Blood Stem Cell Transplantation (PBSCT).. Blood, 2006, 108, 757-757.	1.4	0
164	Approaches to graft-vs-host disease. Pediatric Transplantation, 2005, 9, 71-75.	1.0	8
165	Donor leukocyte infusions and graft-versus-malignancy. Journal of Clinical Apheresis, 2005, 20, 113-116.	1.3	3
166	Immune reconstitution: The major barrier to successful stem cell transplantation. Biology of Blood and Marrow Transplantation, 2005, 11, 43-45.	2.0	19
167	Protective antibody responses to pneumococcal conjugate vaccine after autologous hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation, 2005, 11, 213-222.	2.0	60
168	Pre-Infusion Characteristics of the Predominant Cord Blood Unit Correlate with Hematopoietic Engraftment in the Setting of Non-Myeloablative Double Cord Blood Transplant (DCBT).. Blood, 2005, 106, 3027-3027.	1.4	3
169	HLA-C Mismatch Is Associated with Inferior Outcome after Unrelated Donor Non-Myeloablative Hematopoietic Stem Cell Transplantation.. Blood, 2005, 106, 835-835.	1.4	3
170	Sirolimus and Tacrolimus without Methotrexate as Graft-vs.-Host Disease Prophylaxis after Matched, Unrelated Peripheral Blood Stem Cell Transplantation: Excellent GVHD Control with Low Transplant-Related Morbidity and Mortality.. Blood, 2005, 106, 2051-2051.	1.4	0
171	Comparison of Methotrexate- Versus Sirolimus- Containing Graft-Versus-Host Disease Prophylaxis Regimens after Myeloablative Stem Cell Transplantation.. Blood, 2005, 106, 1797-1797.	1.4	0
172	Efficacy of Performing a Second Non-Myeloablative Allogeneic Stem Cell Transplant.. Blood, 2005, 106, 3664-3664.	1.4	0
173	A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood, 2004, 104, 579-585.	1.4	638
174	Mixed Chimerism Following Nonmyeloablative Stem Cell Transplantation for Sickle Cell Disease Prevents Intravascular Hemolysis and Restores Endothelial Function.. Blood, 2004, 104, 1679-1679.	1.4	8
175	Sirolimus and Thrombotic Microangiopathy after Allogeneic Stem Cell Transplantation.. Blood, 2004, 104, 1834-1834.	1.4	2
176	Rituximab Therapy for Steroid-Refractory Chronic GVHD: Safety and Efficacy Analysis.. Blood, 2004, 104, 2251-2251.	1.4	2
177	Oral Mucositis Incidence and Severity after Methotrexate and Non-Methotrexate Containing GVHD Prophylaxis Regimens.. Blood, 2004, 104, 351-351.	1.4	3
178	Survival Following Etanercept Therapy for the Treatment of Idiopathic Pneumonia Syndrome Post Allogeneic Stem Cell Transplantation.. Blood, 2004, 104, 354-354.	1.4	5
179	The Y-Specific Gene PRY Is Expressed in Normal Blood Cells as Well as Leukemia Cells and Can Elicit a Specific Antibody Response in Male Recipients of Hematopoietic Stem Cells from Female Donors.. Blood, 2004, 104, 4976-4976.	1.4	0
180	Sirolimus and Tacrolimus as Graft-vs.-Host Disease Prophylaxis in Allogeneic Stem Cell Transplantation: The Dana-Farber Cancer Institute Experience.. Blood, 2004, 104, 1227-1227.	1.4	0

#	ARTICLE	IF	CITATIONS
181	High Levels of Donor Chimerism Early after Non-Myeloablative Transplantation Predictive of Overall and Progression Free Survival but Not Risk of Acute Graft Versus Host Disease for Patients with AML or MDS.. Blood, 2004, 104, 185-185.	1.4	0
182	Allogeneic B Cell Response to H-Y Minor Histocompatibility Antigens after Donor Lymphocyte Infusion Correlates with Disease Response.. Blood, 2004, 104, 296-296.	1.4	0
183	Similar Outcome of Non-Myeloablative and Myeloablative Allogeneic Hematopoietic Cell Transplantation for Patients Greater Than Fifty Years of Age.. Blood, 2004, 104, 300-300.	1.4	2
184	Prevention of Acute GVHD with Sirolimus Does Not Abrogate the Risk of Chronic GVHD.. Blood, 2004, 104, 3317-3317.	1.4	0
185	Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study. Blood, 2003, 102, 2768-2776.	1.4	196
186	Long-Term Care after Hematopoietic-Cell Transplantation in Adults. New England Journal of Medicine, 2002, 347, 36-42.	27.0	76
187	Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation. Blood, 2002, 100, 3479-3482.	1.4	167
188	Acute and Chronic Graft-Versus-Host Disease After Allogeneic Peripheral-Blood Stem-Cell and Bone Marrow Transplantation: A Meta-Analysis. Journal of Clinical Oncology, 2001, 19, 3685-3691.	1.6	396
189	Peripheral Blood Stem Cells for Allogeneic Transplantation: A Review. Stem Cells, 2001, 19, 108-117.	3.2	89
190	Engraftment and survival after unrelated-donor bone marrow transplantation: a report from the National Marrow Donor Program. Blood, 2000, 96, 4096-4102.	1.4	191
191	Comparative Outcomes of T-Cellâ€Depleted and Nonâ€T-Cellâ€Depleted Allogeneic Bone Marrow Transplantation for Chronic Myelogenous Leukemia: Impact of Donor Lymphocyte Infusion. Journal of Clinical Oncology, 1999, 17, 561-561.	1.6	108
192	ABO incompatibility as an adverse risk factor for survival after allogeneic bone marrow transplantation. Transfusion, 1999, 39, 179-187.	1.6	101
193	Primary Diffuse Large B-Cell Lymphoma of the Mediastinum: Outcome Following High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation. Blood, 1998, 91, 717-723.	1.4	80
194	A Phase II Study of BTI-322, a Monoclonal Anti-CD2 Antibody, for Treatment of Steroid-Resistant Acute Graft-Versus-Host Disease. Blood, 1998, 92, 4066-4071.	1.4	13
195	Substance Abuse and Bone Marrow Transplant. American Journal of Drug and Alcohol Abuse, 1997, 23, 301-308.	2.1	38
196	Adoptive Immunotherapy for Relapsed Leukemia Following Allogeneic Bone Marrow Transplantation. Leukemia and Lymphoma, 1995, 17, 191-197.	1.3	14
197	The Pathophysiology of Graft-Versus-Host Disease. , 0, , 208-221.		2
198	Secondary Anemias Associated with Hematopoietic Stem Cell Transplantation. , 0, , 179-184.		0